TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Study of Efficacy and Safety of Biologic Drugs in the Therapy of Rheumatoid Arthritis and Spondyloarthritis
Brief Summary: The biologic drugs targeting TNFa, IL-6, IL-1, T cells, B cells have represented a fundamental discovery to treat rheumatic patients whose disease appears to be refractory to conventional therapy. These biologic drugs have been registered for human therapy from a few years, thereby the investigators miss long-term data for safety and efficacy. Aim of this study is to register all the clinical data of patients with rheumatoid arthritis and spondyloarthritis beginning a treatment with biologic drugs in order to assess the long-term safety and efficacy in the real life.


Options:
A: Inclusion Criteria:

* Adults with moderate to severe rheumatoid arthritis on a stable dose of methotrexate

Exclusion Criteria:

* Pregnancy, severe acute or chronic medical conditions, including serious infections or clinically significant laboratory abnormalities.
B: Inclusion Criteria:

* Clinical diagnosis of Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis
* Patients with active disease refractory to traditional disease modifying drugs (methotrexate, leflunomide, sulphasalazine, cyclosporine, hydrossiclorochine)
* Patients eligible to begin conventional biologic therapy

Exclusion Criteria:

* Any criteria excluding treatment with biologic drugs according to international guidelines
C: Inclusion Criteria:

* adult patients \>=18 years of age;
* RA for \>=6 months;
* receiving outpatient treatment;
* inadequate response to methotrexate, having received and tolerated it for \>=12 weeks, with a stable dose for \>=4 weeks.

Exclusion Criteria:

* rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA;
* inflammatory joint disease other than RA, or other systemic autoimmune disorder;
* diagnosis of juvenile arthritis, or RA before the age of 16;
* previous treatment with \>1 biologic agent, any cell-depleting therapies, or concurrent treatment with any biologic agent or DMARD other than methotrexate.
D: Inclusion Criteria:

* Adult patients, ≥ 18 years of age.
* Rheumatoid arthritis of \> 6 months duration.
* Intolerant of methotrexate or continued treatment with methotrexate is considered inappropriate.
* All disease-modifying anti-rheumatic drugs (DMARD) are to be withdrawn prior to receiving study drug.
* Weight ≤ 150 kg.

Exclusion Criteria:

* Major surgery (including joint surgery) within 12 weeks prior to baseline or planned major surgery within 6 months after baseline.
* History of or current inflammatory joint disease other than rheumatoid arthritis (RA).
* Treatment with a biologic agent at any time prior to baseline.
* Intra-articular or parenteral corticosteroids ≤ 4 weeks prior to baseline.
* Active current infection or history of recurrent bacterial, viral, fungal or mycobacterial infection.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Study of Efficacy and Safety of Biologic Drugs in the Therapy of Rheumatoid Arthritis and Spondyloarthritis
Brief Summary: The biologic drugs targeting TNFa, IL-6, IL-1, T cells, B cells have represented a fundamental discovery to treat rheumatic patients whose disease appears to be refractory to conventional therapy. These biologic drugs have been registered for human therapy from a few years, thereby the investigators miss long-term data for safety and efficacy. Aim of this study is to register all the clinical data of patients with rheumatoid arthritis and spondyloarthritis beginning a treatment with biologic drugs in order to assess the long-term safety and efficacy in the real life.


Options:
A: * Rheumatoid Arthritis (RA) for greater than 1 year from the time of initial diagnosis of RA.
* Participants must have been taking methotrexate for at least 3 months with at least a weekly dose of 15 mg.
B: Inclusion Criteria:

* Moderate to severe Rheumatoid arthritis (RA) according to American College of Rheumatology (ACR) criteria
* Methotrexate failure
* Naive to RA biologics
* ≤5 years duration of disease
* Disease Activity Score-28 C-reactive protein (DAS28 CRP) ≥ 3.2
* Willingness to self-inject subcutaneous (SC) drug

Exclusion Criteria:

* Previous or current medical conditions that are warnings against the use of tumor necrosis factor (TNF)-blocking agents
* History of active or chronic hepatitis
* Cancer in the last 5 years
* History of severe chronic or recurrent bacterial or viral infections
* Risk of tuberculosis
* Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, Gastro-intestinal, pulmonary, cardiac, neurologic, or cerebral disease
C: Inclusion Criteria:

* Subjects who have participated in a randomized "qualifying" study of CP-690,550 for the treatment of rheumatoid arthritis

Vaccine sub-study visit

* Subjects actively participating in Study A3921024 must have completed at least 3 months of continuous 10 mg BID CP-690,550 treatment in A3921024 as defined by \>80% compliance with prescribed dose consumption of CP-690,550 over the previous 3 months.

Exclusion Criteria:

* Serious medical conditions that would make treatment with CP-690,550 potentially unsafe

Vaccine sub-study visit

1. Any documented influenza or pneumococcal infection within the last 3 months prior to randomization in this study
2. Received any vaccine within 1 month prior to randomization in this study
3. Received an influenza vaccine within 6 months or a pneumococcal vaccine within 5 years of randomization in this study.
D: Inclusion Criteria:

* Clinical diagnosis of Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis
* Patients with active disease refractory to traditional disease modifying drugs (methotrexate, leflunomide, sulphasalazine, cyclosporine, hydrossiclorochine)
* Patients eligible to begin conventional biologic therapy

Exclusion Criteria:

* Any criteria excluding treatment with biologic drugs according to international guidelines

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy of "Tailored Physical Activity" on the Number of Sick Days: a Randomized Controlled Trial in Health Care Workers That Have Experienced Pain Related to the Spine or Upper Body
Brief Summary: The purpose of this study is to test the effect of "Tailored Physical Activity" on the number of sick-days.

The hypothesis is that "Tailored Physical Activity" is superior in efficacy on sick-days.


Options:
A: Inclusion Criteria:

Health care workers in municipality of Sønderborg that have experienced musculoskeletal pain related to the spine or upper body.

Exclusion Criteria:

Medically safety.
B: Inclusion Criteria:

* Currently employed as a home care worker with a minimum of one consumer employer

Exclusion Criteria:

* None
C: Inclusion Criteria:

* Willing to sign a consent form.
* BMI during screening ≥25 kg/m2 (eligibility for weight loss support group)
* Participants must not have had any surgical procedures influencing weight regulation to include, but not limited to, gastric bypass, other bariatric surgeries, resection of small or large intestine leading to malabsorption, gastric resection for ulcers or cancer, and esophageal resection
* Intention to follow recommended program and complete outcome assessments and requested self-monitoring.
* Obtain a physician's clearance form
D: Inclusion Criteria:

* MGH (benefited) employees who enroll in the Be Fit program
* Able to commit to 1 year of active research participation

Exclusion Criteria:

* Not enrolled in the Be Fit program
* Decline participation in the research study
* Withdrawal from the Be Fit 12 week program prior to completion
* Women who are currently pregnant or suspect they may be pregnant
* Plans to leave MGH within 3 months from enrolling in Be Fit

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy of "Tailored Physical Activity" on the Number of Sick Days: a Randomized Controlled Trial in Health Care Workers That Have Experienced Pain Related to the Spine or Upper Body
Brief Summary: The purpose of this study is to test the effect of "Tailored Physical Activity" on the number of sick-days.

The hypothesis is that "Tailored Physical Activity" is superior in efficacy on sick-days.


Options:
A: Inclusion Criteria:

Health care workers in municipality of Sønderborg that have experienced musculoskeletal pain related to the spine or upper body.

Exclusion Criteria:

Medically safety.
B: Inclusion Criteria:

* living in the counties of Trøndelag
* on sick leave 2-12 months
* current sick leave status of 50% - 100%
* ICPC-2 (International Classification of Primary Care, Second edition) diagnosis within the L (musculoskeletal), P (psychiatric) or A (unspecific disorders) categories

Exclusion Criteria:

* alcohol or drug abuse
* serious somatic or psychological disorders
* a specific disorder requiring specialized treatment
* pregnancy
* currently participating in another treatment program
* insufficient Norwegian speaking or writing skills to participate in group session and fill out questionnaires
* scheduled for surgery within the next 6 months
* serious problems with functioning in a group setting
C: Inclusion Criteria:

* A score of 5 or more on SCL-8AD

Exclusion Criteria:

* Sick listed due to psychiatric symptoms in a period of 3 months or longer in the last year
* pregnant
* has a flexible job
* receive pension
* not communicating in Danish
D: Inclusion Criteria:

* employment
* sick leave at lest half time 2-6 months due to work related burnout
* previously healthy

Exclusion Criteria:

* other somatic or psychiatric disease explaining the symptoms

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Improving Adherence to Web-Based Cessation Programs: A Social Network Approach
Brief Summary: This study will compare the efficacy of an interactive, evidence-based smoking cessation website (WEB) alone and in conjunction with 1) a theory-driven, empirically-informed social network (SN) protocol designed to integrate participants into the online community, and 2) access to a 4-week supply of free NRT.


Options:
A: Inclusion Criteria:

* Age 18 years and older
* Current smoker
* Registered user on BecomeAnEX.org

Exclusion Criteria:

* Pregnant or breastfeeding
* Cardiovascular conditions
* Current use of any stop smoking medication
B: Inclusion Criteria:

* Facebook user
* Age 18 years or older
* Entered UbiQUITous Facebook Application
* Confirms smoker status
* U.S. resident

Exclusion Criteria:

* Non-smoker
* Under 18 years old
* Non-U.S. resident
* Non-Facebook advertisement point of entry
C: Inclusion Criteria:

* must have smoked 100 cigarettes during their lifetime
* must currently smoke 5 or more cigarettes a day
* must be in the preparation stage of quitting smoking
* ages 18-59 years
* English speaking
* have a mobile phone with an unlimited texting plan and internet access
* use text messaging at least once a week
* use Facebook daily
* have an active email account
* live in the continental USA

Exclusion Criteria:

* a medical condition that is contra-indicated for nicotine replacement therapy:
* pregnant
* breast feeding
* a recent heart attack
* an irregular heartbeat
* high blood pressure not controlled with medication
* skin allergies to adhesive tape or serious skin problems
* taking a prescription medicine for depression or anxiety
* use drugs or marijuana regularly
* live in the same household with another participant
D: Inclusion Criteria:

* self-identified Korean American ethnicity
* age 18 years or older
* daily smoker (i.e., smoked at least one cigarette per day during the previous seven days)
* current U.S. resident
* valid email address
* regular internet access.

Exclusion Criteria: None

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Improving Adherence to Web-Based Cessation Programs: A Social Network Approach
Brief Summary: This study will compare the efficacy of an interactive, evidence-based smoking cessation website (WEB) alone and in conjunction with 1) a theory-driven, empirically-informed social network (SN) protocol designed to integrate participants into the online community, and 2) access to a 4-week supply of free NRT.


Options:
A: * INCLUSION CRITERIA

At least 18 years of age

Resident of the District of Columbia or Greater Metropolitan Area

Minority Woman (Either African American or Hispanic)

No more than 30 weeks estimated gestational age

Able to read and speak English

Current cigarette smoker

Baseline saliva continine level equal to or exceeding 30 ng/ml

Expresses desire to quit smoking in this pregnancy

EXCLUSION CRITERIA

Currently participating in any other smoking cessation treatment program

Has the following conditions: heart disease, irregular heart beat, high blood pressure, diabetes, liver condition, kidney condition, stomach ulcer, asthma, chronic pulmonary disease, or skin condition

Currently being treated for psychiatric illness, alcoholism, or other drug addiction.
B: Inclusion Criteria:

* 18 years or older
* Smoke \>=6 Cigarettes per day
* English or Spanish speaking
* Valid phone number
* Valid address
* Gave consent to participate in study and evaluation

Exclusion Criteria:

* Hospital stay of less than 24 hours
* Inability to communicate orally
* Hypersensitivity to nicotine
* Pregnant
* Hospitalized for psychiatric treatment
C: Inclusion Criteria:

* Age 18 years and older
* Current smoker
* Registered user on BecomeAnEX.org

Exclusion Criteria:

* Pregnant or breastfeeding
* Cardiovascular conditions
* Current use of any stop smoking medication
D: Inclusion Criteria:

* smoking pregnant woman unable to quit smoking during the first 3 months of pregnancy
* smoking ≥ 5 cigaret/day despite standard medical advice and cognitive-behavioral counselling
* aged ≥ 18 years
* health insured
* motivated to stop smoking; motivation score ≥ 5 on a scale ranging from 0 to 10
* amenorrhea of 9 to 20 weeks
* having signed the written informed consent

Exclusion Criteria:

* non-pregnant women
* men

Pregnant woman:

* who does not agree to use a nicotine or placebo patch
* with presence of chronic psychiatric comorbidity treated continuously by antidepressant, neuroleptic or anxiolytic
* with skin disorder contraindicating the use of a transdermal patch
* with known hypersensitivity to transdermal patch or to one of its constituents
* using other nicotine containing pharmaceutical products (gum, lozenge, inhaler, sublingual tablets)
* using other forms of tobacco than cigaret (cigaret, pipe or any form of smokeless tobacco)

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Does Office Hysteroscopy and Endometrial Snip Improve IUI Outcome? : a Randomized Controlled Trial
Brief Summary: Endometrial injury had been studied before prior to intracytoplasmic sperm injection (ICSI) cycles , in cases of repeated implantation failure. It is found that it will improve the implantation rate.


Options:
A: Inclusion Criteria:

* 18- 38 years old
* at least one patent tube
* unexplained infertility, anovulation, mild to moderate male factor infertility
* previous failed IUI

Exclusion Criteria:

* indicated for ICSI
B: Inclusion Criteria:

* Women indicated for a first IVF/ICSI treatment
* Primary or secondary infertility
* Normal Transvaginal Ultrasound, performed in the follicular phase of the menstrual cycle

Exclusion Criteria:

* Recurrent miscarriage
* Prior hysteroscopy treatments
* Meno-metrorrhagia (defined as any intermenstrual loss of blood)
C: Inclusion Criteria:adult female, referred for outpatient diagnostic hysteroscopy, subscriber to Maccabe health maintenance organization -

Exclusion Criteria:heavy vaginal bleeding; severe cervical stenosis; patients refusing the examination on an outpatient basis.

-
D: Inclusion Criteria:

* Finding of a benign polyp on diagnostic hysteroscopy
* Patient considered able to tolerate outpatient hysteroscopic polypectomy based upon the response to preliminary diagnostic hysteroscopy. NB. all polyps diagnosed at hysteroscopy will be considered feasible to remove in the outpatient setting regardless of size, location or number. Patient factor(s) will be the only exclusion criteria following the diagnosis of benign, uterine polyp(s).
* Need for polypectomy
* Written informed consent

Exclusion Criteria:

• Hysteroscopic features suggesting malignant lesion

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Does Office Hysteroscopy and Endometrial Snip Improve IUI Outcome? : a Randomized Controlled Trial
Brief Summary: Endometrial injury had been studied before prior to intracytoplasmic sperm injection (ICSI) cycles , in cases of repeated implantation failure. It is found that it will improve the implantation rate.


Options:
A: Inclusion Criteria:

* Age \< 35
* First IVF cycle
* Long protocol should be used for stimulation

Exclusion Criteria:

* Day 3 FSH \> 10
B: Inclusion Criteria:

* Women with history of primary or secondary infertility undergoing fresh IVF/ ICSI treatment or frozen embryo replacement cycle
* Age \<49

Exclusion Criteria:

* Non- ovulatory cycles
* Absent uterus
* Uterine instrumentation within previous 3 menstrual cycles
* Women in the oocyte donation program
C: Inclusion Criteria:

* 18- 38 years old
* at least one patent tube
* unexplained infertility, anovulation, mild to moderate male factor infertility
* previous failed IUI

Exclusion Criteria:

* indicated for ICSI
D: Inclusion Criteria:

* Previous failed In-vitro fertilization embryo transfer cycle
* Patients who are good responders and have good quality embryos in the previous attempts
* Age of patients upto 37yrs

Exclusion Criteria:

* Those detected to have endometrial tuberculosis in the past, including those treated with Antituberculosis treatment
* Those with intramural fibroid distorting the endometrial cavity/sub-mucous myoma
* Those with sonographically detected hydrosalpinx

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Does Office Hysteroscopy and Endometrial Snip Improve IUI Outcome? : a Randomized Controlled Trial
Brief Summary: Endometrial injury had been studied before prior to intracytoplasmic sperm injection (ICSI) cycles , in cases of repeated implantation failure. It is found that it will improve the implantation rate.


Options:
A: Inclusion Criteria:

* women aged between 20 and 39 years with at least one year of infertility
* regular menstruation with the length of the cycle between 22-34 days and ovulation confirmed by appropriately timed mid-luteal progesterone
* fertile semen variables
* bilateral tubal patency (demonstrated by laparoscopy or hysterosalpingography).
B: Inclusion Criteria:

* Women ages 18 and over who present to the Oregon Health and Science University Center for Women's Health and the Portland Veteran's Affairs Medical Center with an indication for endometrial biopsy, are literate in English or Spanish, who are willing to participate in the study.

Exclusion Criteria:

* Pregnancy, known or suspected
* Known cervical stenosis
* History of Mullerian tract anomalies
* History of uterine or cervical surgery
* Pelvic inflammatory disease (current or within the past 3 months)
* Sexually transmitted diseases (current)
* Puerperal or post abortion sepsis (current or within the past 3 months)
* Purulent cervicitis (current)
* Known clotting disorder
* Known uterine anomalies or fibroids distorting the cavity in a way incompatible with office endometrial biopsy
* Allergy to any component of the Pipelle or Explora curette
* Patients who are premedicated with analgesics or misoprostol
* Patients who require mechanical cervical dilation or receive paracervical block
C: Inclusion Criteria:

1. Male partner should have a normal semen count and motility according to world health organization criteria (Murray et al., 2012).
2. Primary, secondary or unexplained infertility for at least one year.
3. Failure to conceive with clomiphene citrate in spite of good follicular response for at least 3 cycles.
4. Age varies from 20-35 years with at least one year of infertility.
5. Body mass index between 19-30 kg/m2.
6. Day 2 serum FSH\< 12 IU/ml.
7. Normal uterine cavity on hystrosalpingography.
8. At least one patent tube of normal appearance on HSG.
9. No previous attempts of intrauterine insemination (IUI) or in vitro fertilization (IVF).

Exclusion Criteria:

1. Infertility due to tubal factor or male factor.
2. Intrauterine organic pathology (myoma, polyp, adhesions) by hystrosalpingogram or diagnostic hysteroscope.
3. Hypogonadotrophic hypogonadism.
D: Inclusion Criteria:

* 18- 38 years old
* at least one patent tube
* unexplained infertility, anovulation, mild to moderate male factor infertility
* previous failed IUI

Exclusion Criteria:

* indicated for ICSI

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX)
Brief Summary: The North Carolina Immunization Branch will evaluate the use of the CDC program to improve adolescent vaccination practices (called Assessment, Feedback, Incentives, and eXchanges, or AFIX). This evaluation is the first of its kind in the nation and may have a profound impact on prevention.

AFIX has four major components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement.

This program will evaluate the effectiveness of AFIX visits on affecting provider practices to increase adolescent (age 11-18) immunization. Visits include discussion of that practice's immunization rates and strategies for improving rates. The investigators will compare the changes, from baseline to 5 months, in immunization for practices receiving virtual visits (webinars), in-person visits, and no visits (control group). Thirty practices will be randomly assigned to each intervention type. The main outcomes of this study are practice-wide uptake rates of several adolescent vaccines (Tdap, HPV, and MCV4) as well as pre- and post-AFIX visit surveys focusing on recall tactics utilized by each practice. Data will be collected on practices with at least 200 adolescent patients (note: there is no patient-level data collected in this study).


Options:
A: Inclusion Criteria:

* First year students in upper secondary school who visit the school nurse for the regular health interview.
* Master Swedish in speech and writing.

Exclusion Criteria:

* Students with cognitive disabilities.
B: Inclusion Criteria:

* female pupil
* attends selected school
* born in 1998 if enrolled in school selected for age-based delivery
* attending standard (class) 6 if enrolled in school selected for class-based delivery

Exclusion Criteria:

* has not previously received HPV vaccine
* has not participated in previous HPV vaccine trials
C: Inclusion Criteria:

* 11-15 years of age
* receive medical care at one of the 9 pediatric or family medicine practices identified as study sites
D: Inclusion Criteria:

* Pediatric and/or family practices participating in the North Carolina Immunization Program
* A minimum of 200 active adolescent patients

Answer: D